Summary:
The purpose of this research is to compare the study drug (amlitelimab) to placebo (a similar looking subcutaneous injection without active study drug) and test if amlitelimab can improve or prevent bowel damage in people with non-responsive celiac disease (NRCD). The study will also look at the effect of amlitelimab on the symptoms of the celiac disease and the safety of amlitelimab in participants with cdliac disease.
Qualified Participants Must:
• Participants with physician-diagnosed CeD with documented history of biopsy-proven CeD confirmed by medical records or physician statement
• Participants who have self-reported attempt to maintain a GFD (and confirmed via questionnaire) for at least 12 consecutive months and must be willing to maintain their current diet for the duration of study participation
• Participants willing to undergo all assessments in the protocol, including 2 esophagogastroduodenoscopies with duodenal biopsies.
Qualified Participants May Receive:
$150.00 For Every Completed Study; Reimbursement for Transportation or Ride-Share, Study Treatment, and diagnostic testing (Including Endoscopy), at no cost to the participants.